COV — CLEO Diagnostics Income Statement
0.000.00%
Last trade - 00:00- AU$56.54m
- AU$49.23m
- AU$0.60m
- 55
- 12
- 54
- 37
Annual income statement for CLEO Diagnostics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 0 | 0.11 | 0.6 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Depreciation and Amortization | |||
| Total Operating Expenses | 0.023 | 1.69 | 4.21 |
| Operating Profit | -0.023 | -1.58 | -3.61 |
| Total Net Non Operating Interest Income / Expense | |||
| Other Net Non Operating Costs | |||
| Net Income Before Taxes | -0.044 | -1.73 | -3.76 |
| Provision for Income Taxes | |||
| Net Income After Taxes | -0.044 | -1.73 | -3.76 |
| Net Income Before Extraordinary Items | |||
| Net Income | -0.044 | -1.73 | -3.76 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -0.044 | -1.73 | -3.76 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -0 | -0.013 | -0.029 |